Sponsors
The bill speeds access to covered treatments and reduces administrative hurdles for patients and providers by banning prior authorization and step therapy for covered services, but it raises fiscal costs, risks of overuse and inappropriate care, and near‑term operational disruption that could translate into higher premiums, greater federal spending, and system strain.
People with chronic or acute conditions — including Medicare and Medicaid beneficiaries — will get faster access to prescribed, covered treatments because plans and federal programs can no longer require prior authorization or step‑therapy for covered services.
Hospitals, health systems, and clinicians will likely face reduced administrative burden and faster care delivery because insurers and federal programs cannot impose medical necessity reviews or other utilization management for covered services.
Insurers and federal programs may face higher costs from paying for more services without utilization controls, which could increase federal spending and lead to higher premiums for enrollees.
Removing utilization management could increase use of low‑value or inappropriate services, producing unnecessary patient harms, higher out‑of‑pocket costs, and added strain on hospital and health system resources.
Employers that sponsor group health plans may face higher premiums or more constrained benefit design, which could reduce other employee compensation or shift costs onto workers.
Based on analysis of 2 sections of legislative text.
Introduced January 22, 2025 by Jefferson Van Drew · Last progress January 22, 2025
Prohibits prior authorization, utilization management (including step‑therapy or fail‑first protocols), and medical necessity reviews for any covered item or service under group or individual health plans and under Federal health care programs and the title 5 U.S.C. health program. The ban for Federal health care programs is effective January 1, 2026; the ban for private group and individual plans applies to plan years beginning on or after January 1, 2026. The change would remove common insurer tools used to control access and costs, likely speeding patient access to some treatments and reducing administrative burdens for clinicians, while shifting utilization-control responsibilities back to payers and potentially raising costs or premiums. The text does not create new funding or specify enforcement mechanisms beyond adding the statutory prohibition.